Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.41 |
| ▸ | JAK2 | O60674 | 11/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 6/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16947090 | 1.00 | NTRK1 (0.41) | NTRK1JAK2KDM4ELMNATDP1 | |
| SCHEMBL16947001 | 0.90 | IRAK4 (0.42) | NTRK1JAK2NTRK3NTRK2IRAK4 | |
| SCHEMBL16946747 | 0.87 | NTRK1 (0.39) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL22201908 | 0.87 | NTRK1 (0.39) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL16946999 | 0.85 | CXCR3 (0.39) | NTRK1JAK2NTRK3 | |
| SCHEMBL16947088 | 0.82 | RBP4 (0.39) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL21942124 | 0.82 | RBP4 (0.36) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL20903455 | 0.81 | NTRK1 (0.39) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL21510192 | 0.80 | JAK2 (0.39) | NTRK1JAK2NTRK3NTRK2 | |
| SCHEMBL21941661 | 0.78 | JAK2 (0.42) | NTRK1JAK2LMNAIRAK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | NTRK1 935/4885JAK2 85/4885KDM4E 1642/4885 |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885JAK2 60/4885KDM4E 1402/4885 |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885JAK2 60/4885KDM4E 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.